Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer
Status:
Unknown status
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
To assess the usefulness of irinotecan plus S-1 therapy based on the antitumor effect and
survival period. by performing a phase II study of this combination in patients with
inoperable or with postoperative colorectal cancer.